Johnson & Johnson said on Monday it had filed a lawsuit against Samsung Bioepis for breaching its contract agreement with the ...
In a report released today, David Amsellem from Piper Sandler reiterated a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a ...
In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Teva Pharmaceutical (TEVA – Research Report), with a price ...
Duquesne Family Office's billionaire chief shed a trillion-dollar artificial intelligence (AI) stock in favor of a ...
Insider Monkey on MSN6d
Is Teva Pharmaceutical (TEVA) Trading at a Discount?Sound Shore Management, an investment management firm, has released its investor letter for the fourth quarter of 2024. A ...
Teva Pharmaceuticals and Alvotech said on Friday they have launched a biosimilar to Johnson & Johnson's autoimmune drug Stelara in the United States, the second in a wave of near-copies of the ...
Pharmaceutical Technology on MSN1d
Teva and Alvotech launch ustekinumab biosimilar injection in USTeva Pharmaceuticals and Alvotech have announced the US launch of Selarsdi (ustekinumab-aekn) injection, a biosimilar to ...
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
In its fourth quarter 2024 investor letter, Sound Shore Management emphasized stocks such as Teva Pharmaceutical Industries Limited (NYSE:TEVA). Headquartered in Tel Aviv, Israel, Teva ...
GlobalData on MSN1d
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitugSanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Teva (TEVA) stock and Alvotech (ALVO) stock in focus as duo launches Selarsdi, a biosimilar to J&J's (JNJ) Stelara after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback